Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

 

Microbial imbalance of the intestinal biome is a key associated factor in many chronic conditions including Myalgic Encephalomyelitis (ME/CFS).  Our major research goals are too increase our understanding of ME/CFS and open up new treatment options. If a leaky gut is a key component of ME/CFS, restoring a normal gut microbiome balance could be a life changing treatment options. Our collaborator SoftCell Biologicals Research (SBR) have developed approaches examining the host tissue biome. This is an un-tapped area of medicine with the presence of significant levels of wall-less (L-Form) opportunistic pathogens present in many chronic disease states. Using novel L-Form culturing methods SBR have treated L-form cultures from patients with chronic urinary tract infections (CURTIs) using a standard antibiotic panel. Clinicians acting on this information have noticed improvements in a number of patients. Clinical studies, using this approach will allow antibiotics tested in the laboratory to be used to treat patients in a blinded trial setting. In this presentation, I will highlight our research with the Doveclinic exploring levels of gut dysbiosis in a broad range of conditions many of whom suffer with fatigue. The impact of age and sex on the gut microbiome will be explored with a focus on ME/CFS and cancer. Exciting data from a comparison of recent trials of Gut Floral Replacement Therapy (GFTR) to the more conventional Faecal Microbiota transplantation (FMT) will be presented.